These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

168 related articles for article (PubMed ID: 38410508)

  • 21. A systematic review and meta-analysis of prognostic indicators in patients with head and neck malignancy treated with immune checkpoint inhibitors.
    Kang D; Liu S; Yuan X; Liu S; Zhang Z; He Z; Yin X; Mao H
    J Cancer Res Clin Oncol; 2023 Dec; 149(20):18215-18240. PubMed ID: 38078963
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Effects of Antibiotic Use on Outcomes in Cancer Patients Treated Using Immune Checkpoint Inhibitors: A Systematic Review and Meta-Analysis.
    Yu Y; Zheng P; Gao L; Li H; Tao P; Wang D; Ding F; Shi Q; Chen H
    J Immunother; 2021 Feb-Mar 01; 44(2):76-85. PubMed ID: 33208635
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Novel evidence for the prognostic impact of β-blockers in solid cancer patients receiving immune checkpoint inhibitors.
    Yan X; Liu P; Li D; Hu R; Tao M; Zhu S; Wu W; Yang M; Qu X
    Int Immunopharmacol; 2022 Dec; 113(Pt A):109383. PubMed ID: 36330916
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Sarcopenia and prognosis of advanced cancer patients receiving immune checkpoint inhibitors: A comprehensive systematic review and meta-analysis.
    Deng HY; Chen ZJ; Qiu XM; Zhu DX; Tang XJ; Zhou Q
    Nutrition; 2021 Oct; 90():111345. PubMed ID: 34166897
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Prognostic significance of programmed cell death ligand 1 blood markers in non-small cell lung cancer treated with immune checkpoint inhibitors: a systematic review and meta-analysis.
    Zhang N; Chang J; Liu P; Tian X; Yu J
    Front Immunol; 2024; 15():1400262. PubMed ID: 38915398
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Antibiotic administration shortly before or after immunotherapy initiation is correlated with poor prognosis in solid cancer patients: An up-to-date systematic review and meta-analysis.
    Yang M; Wang Y; Yuan M; Tao M; Kong C; Li H; Tong J; Zhu H; Yan X
    Int Immunopharmacol; 2020 Nov; 88():106876. PubMed ID: 32799113
    [TBL] [Abstract][Full Text] [Related]  

  • 27. The impact of antibiotic use on clinical features and survival outcomes of cancer patients treated with immune checkpoint inhibitors.
    Zhou J; Huang G; Wong WC; Hu DH; Zhu JW; Li R; Zhou H
    Front Immunol; 2022; 13():968729. PubMed ID: 35967438
    [TBL] [Abstract][Full Text] [Related]  

  • 28. A Novel Prognostic Model Using Pan-Immune-Inflammation Value and Programmed Death Ligand 1 in Patients with Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma Receiving Immune Checkpoint Inhibitors: A Retrospective Multicenter Analysis.
    Lien MY; Hwang TZ; Wang CC; Hsieh CY; Yang CC; Wang CC; Lien CF; Shih YC; Yeh SA; Hsieh MC
    Target Oncol; 2024 Jan; 19(1):71-79. PubMed ID: 38041732
    [TBL] [Abstract][Full Text] [Related]  

  • 29. The predictive value of tumor mutation burden on survival of gastric cancer patients treated with immune checkpoint inhibitors: A systematic review and meta-analysis.
    Ke L; Li S; Huang D
    Int Immunopharmacol; 2023 Nov; 124(Pt B):110986. PubMed ID: 37748223
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Peripheral cytokine levels as novel predictors of survival in cancer patients treated with immune checkpoint inhibitors: A systematic review and meta-analysis.
    Mao XC; Yang CC; Yang YF; Yan LJ; Ding ZN; Liu H; Yan YC; Dong ZR; Wang DX; Li T
    Front Immunol; 2022; 13():884592. PubMed ID: 36072577
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Pretreatment hematological markers predict clinical outcome in cancer patients receiving immune checkpoint inhibitors: A meta-analysis.
    Tan Q; Liu S; Liang C; Han X; Shi Y
    Thorac Cancer; 2018 Oct; 9(10):1220-1230. PubMed ID: 30151899
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Biomarkers predicting clinical outcomes in nasopharyngeal cancer patients receiving immune checkpoint inhibitors: A systematic review and meta-analysis.
    Qian X; Chen H; Tao Y
    Front Immunol; 2023; 14():1146898. PubMed ID: 37063822
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Prognostic relevance of prognostic nutritional indices in gastric or gastro-esophageal junction cancer patients receiving immune checkpoint inhibitors: a systematic review and meta-analysis.
    Hou S; Song D; Hao R; Li L; Zhang Y; Zhu J
    Front Immunol; 2024; 15():1382417. PubMed ID: 38966640
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Myeloid-derived suppressor cells in peripheral blood as predictive biomarkers in patients with solid tumors undergoing immune checkpoint therapy: systematic review and meta-analysis.
    Möller M; Orth V; Umansky V; Hetjens S; Braun V; Reißfelder C; Hardt J; Seyfried S
    Front Immunol; 2024; 15():1403771. PubMed ID: 38855104
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Evaluating liver function and the impact of immune checkpoint inhibitors in the prognosis of hepatocellular carcinoma patients: A systemic review and meta-analysis.
    Tian BW; Yan LJ; Ding ZN; Liu H; Han CL; Meng GX; Xue JS; Dong ZR; Yan YC; Hong JG; Chen ZQ; Wang DX; Li T
    Int Immunopharmacol; 2023 Jan; 114():109519. PubMed ID: 36459922
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Predictive value of inflammation and nutritional index in immunotherapy for stage IV non-small cell lung cancer and model construction.
    Lei W; Wang W; Qin S; Yao W
    Sci Rep; 2024 Jul; 14(1):17511. PubMed ID: 39080372
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Prognostic value of
    Ling T; Zhang L; Peng R; Yue C; Huang L
    Front Immunol; 2022; 13():1014063. PubMed ID: 36466905
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Effects of glucocorticoid use on survival of advanced non-small-cell lung cancer patients treated with immune checkpoint inhibitors.
    Li N; Zheng X; Gan J; Zhuo T; Li X; Yang C; Wu Y; Qin S
    Chin Med J (Engl); 2023 Nov; 136(21):2562-2572. PubMed ID: 37925595
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Prognosis stratification of cancer patients treated with immune checkpoint inhibitors through lung immune prognostic index: a meta-analysis and systematic review.
    Guo Y; Pan Y; Wan J; Gong B; Li Y; Kan X; Zheng C
    BMC Cancer; 2024 Apr; 24(1):523. PubMed ID: 38664760
    [TBL] [Abstract][Full Text] [Related]  

  • 40. The role of ERBB4 mutations in the prognosis of advanced non-small cell lung cancer treated with immune checkpoint inhibitors.
    Hu X; Xu H; Xue Q; Wen R; Jiao W; Tian K
    Mol Med; 2021 Oct; 27(1):126. PubMed ID: 34620079
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.